A breakthrough in the treatment of multidrug-resistant tuberculosis: A novel and effective approach

Abstract

The resistant to multidrug-resistant mycobacterium tuberculosis (MDR) strains has affected to the control on tuberculosis (TB). Drugs such as isoniazid and rifampin are commonly used for the therapy in TB. In these, in the phenomenon of the production of anti-TB drugs, the maintenance of the records is one of the challenging steps. The estimated global incidences of nearly half million are witnesses for MDR/rifampicin-resistant TB. This article included the global problem of the drug resistant to TB with its lengthy, complicated, and life-threatening effects with its poor results. Recently new medicines have been developed after a long time on the treatment of TB in MDR resistance. Levofloxacin, moxifloxacin, bedaquiline, delamanid, linezolid, and other second-line medications for TB treatment include levofloxacin, moxifloxacin, bedaquiline, delamanid, linezolid, and others. In the case of MDR-TB, a variety of medications are advised. In the treatment of TB, these medications are effective anti-TB drugs. The goal of this study is to analyze MDR-TB treatment methods in light of WHO guidelines for MDR-TB care in 2021.